OncoGenex Pharmaceuticals has published some positive pre-clinical data in the journal Cell Death and Disease regarding their investigational compound OGX-427 against pancreatic cancer.
OGX-427 is a compound that is meant to lower the level of hear shock protein 27 (Hsp27), a protein found expressed on several tumor types. Early theories argue that overexpression of this protein leads to treatment resistance. Furthermore, expression of Hsp27 has been correlated with tumor cell growth.
In the published data, researchers at OncoGenex have shown that single-agent OGX-427 can cut the levels of the protein and reduce some tumors by 50%.
While this pre-clinical data supports the efficacy of OGX-427 against pancreatic cancers, prior pre-clinical work has shown a similar efficacy against lung, prostate and bladder cancers as well.
OncoGenex is currently also running three clinical trials of OGX-427—one Phase I trial against superficial bladder cancer, a Phase II trial against prostate cancer and another Phase II trial against metastatic bladder cancer.
For more information, go to www.oncogenex.com.
Source: Therapeutics Daily
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
